A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Inclusion Criteria

• Adequate liver, kidney and hematology function per laboratory values as described in the protocol.
• Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
• - Received prior alemtuzumab (unless unsuitable or unavailable).
• Has no malignancies other than T-PLL that:
• currently require systemic therapies;
• were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or
• developed signs of progression after curative treatment.

Exclusion Criteria

• History of or current decompensated cirrhosis including Child-Pugh class B or C, ascites, hepatic encephalopathy, or variceal bleeding.
• Has human T-cell lymphotropic virus, type 1.
• Prior allogeneic stem cell transplant within 6 months of study drug administration and requirement for graft versus host therapy.
• Has an uncontrolled or active infection including severe acute respiratory syndrome- coronavirus-2 (SARS-COV-2).
• Previously treated with a B-cell lymphoma (BCL)-2 inhibitor.
• Received a prohibited therapy within the specified time frame as described in the protocol.